Wednesday, 29 July 2015

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Diffuse Large B-Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015.


- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned
AbbVie Inc. Affimed Therapeutics AG Amgen Inc. Aprogen, Inc. Arrien Pharmaceuticals, LLC Astellas Pharma Inc. AstraZeneca Plc Aurigene Discovery Technologies Limited Bayer AG BIND Therapeutics, Inc. Biocon Limited Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation Cell>Point, L.L.C. Cellular Biomedicine Group, Inc. Constellation Pharmaceuticals, Inc. CTI BioPharma Corp. CureTech Ltd. Curis, Inc. Eisai Co., Ltd. EpiZyme, Inc. Erytech Pharma SA F. Hoffmann-La Roche Ltd. Genentech, Inc. Gilead Sciences, Inc. GlaxoSmithKline Plc Idera Pharmaceuticals, Inc. ImmunoGen, Inc. Immunomedics, Inc. Immunovaccine, Inc. Incyte Corporation Infinity Pharmaceuticals, Inc. Johnson & Johnson Karus Therapeutics Limited Karyopharm Therapeutics, Inc. Kite Pharma, Inc. Mabion SA MedImmune, LLC Merck & Co., Inc. Millennium Pharmaceuticals, Inc. Mirati Therapeutics Inc. Mirna Therapeutics, Inc. Molplex Ltd. MorphoSys AG Nimbus Therapeutics, LLC Nordic Nanovector AS Novartis AG Ono Pharmaceutical Co., Ltd. Onyx Pharmaceuticals, Inc. Pfizer Inc. Pharmacyclics, Inc. Philogen S.p.A. Portola Pharmaceuticals, Inc. Priaxon AG ProNAi Therapeutics, Inc. RedHill Biopharma Ltd. Redx Pharma Ltd Respiratorius AB Rhizen Pharmaceuticals SA Sandoz International GmbH Seattle Genetics, Inc. Taiho Pharmaceutical Co., Ltd. TG Therapeutics, Inc.

Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home